{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"21.1","upperLimit":"42.7","value":"31.2"},{"groupId":"OG001","lowerLimit":"18.6","upperLimit":"49.1","value":"32.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Confirmed ORR is defined as the proportion of participants in each cohort who have a confirmed CR or confirmed PR, as determined by investigator assessment per RECIST 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Confirmed Objective Response Rate(ORR) Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}